HealthcareJul 17, 2026

AMICUS THERAPEUTICS, INC

Company Profile Analysis

Book Demo Subscribe Now

AMICUS THERAPEUTICS, INC - Healthcare showcase

Year Founded & Workforce

2001-12-31

1,000 Employees

Industry

Healthcare

Services

AMICUS THERAPEUTICS, INC Overview

Company Headquarters: Cranbury, US

Workforce: ~1,000

Founded: 2002

Company Working:Amicus Therapeutics, Inc (Amicus) is an international, patient-dedicated biotechnology company that develops and delivers innovative, high-quality medications for patients living with rare metabolic diseases. Amicus expanded its business in 27 countries across the globe with headquarters in Cranbury, US. The company’s international offices are located in Canada, Germany, France, Australia, Japan, Italy, the Netherlands, and Spain.

Strategy

Amicus Therapeutics, Inc strategizes to innovate, manufacture, test, and deliver the best quality medicines for people living with rare metabolic diseases. It is also, dedicated to growing a strong pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic disorders such as Pompe and Fabry disease. Amicus focuses on enhancing the clinical data for AT-GAA in ongoing clinical studies to deliver new therapy for people living with Pompe disease.

Company Snapshot

$4.96M

Revenue

1,000

Employees

2001-12-31

Founded

Cranbury, US

Headquarters

SWOT Analysis

Strengths

Strong R&D base
Portfolio comprises high-quality medicines for rare diseases

Weaknesses

Flaws in the management

Opportunities

Expansion opportunities in low economies
Partnership with other players to diversify its business

Threats

Strict government regulations associated with product approvals

Key Developments

Date	Approach	Development
–	Expansion	Amicus and the University of Pennsylvania announced a major expansion of their collaboration with rights to pursue collaborative research and development of novel gene therapies for lysosomal disorders (LDs) and 12 additional rare diseases, including Pompe disease.
–	Patent	Amicus received two new patents for Pompe Enzyme ATB200. These patents provided Amicus with the long-term intellectual property rights that enabled it to significantly strengthen its position in the global Pompe disease treatment market.

Product Offering

AMICUS THERAPEUTICS, INC
- AT-GAA (Novel ERT + Chaperone)
- Pompe Gene Therapy Andago

Financial Performance

A plan for every need

Forecast+

Get unlimited access to forecasts, charts, and company data across every research report on Wantstats.

USD200/mo

About the Author

Wantstats Research Team

Wantstats' research desk profiles AMICUS THERAPEUTICS, INC as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

AMICUS THERAPEUTICS, INC

Company Headquarters: Cranbury, US Workforce: ~1,000 Founded: 2002 Company Working:Amicus Therapeutics, Inc (Amicus) is an international, patient-dedicated biotechnology company that develops and delivers innovative, high-quality medications for patients living with rare metabolic diseases. Amicus expanded its business in 27 countries across the globe with headquarters in Cranbury, US. The company’s international offices are located in Canada, Germany, France, Australia, Japan, Italy, the Netherlands, and Spain.

Starting from

$4,950